Previous 10 | Next 10 |
Image source: The Motley Fool. Agenus inc (NASDAQ: AGEN) Q2 2021 Earnings Call Aug 9, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Agenus inc (AGEN) Q2 2021 Earnings Call Transcript
Agenus Inc. (AGEN) Q2 2021 Earnings Conference Call August 9, 2021 8:30 AM ET Company Participants Jan Medina – Director-Investor Relations Garo Armen – Chairman and Chief Executive Officer Jennifer Buell – President and Chief Operating Officer Andy Hurley – Chief ...
$200M received from BMS for anti-TIGIT bispecific antibody collaboration FDA cleared IND for AGEN1777 clinical enrollment AGEN1181 rapidly advancing in the clinic; data to be presented in 2H 2021 Cell therapy subsidiary MiNK Therapeutics filed confidential S-1 for planned IP...
LEXINGTON, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Jennife...
NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics today announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC") relating to the proposed initial public offering of its common stock. The num...
Even on a generally downbeat day for the stock market, Agenus (NASDAQ: AGEN) was quite a downer on Tuesday. The biotech company's shares fell by just over 6% on the day because of a notable C-suite departure. Agenus announced in a tersely worded regulatory filing that chief lega...
LEXINGTON, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that it will rel...
Biotech stocks had a muted first half with the S&P Biotech Index down year-to-date, and more than 20% lower from its mid-February peak. The decline in biotech stocks coincided with a spike in interest rates and stabilizing interest rates can provide a boost to valuations. M&am...
LEXINGTON, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Steven ...
Drew Angerer/Getty Images News Agenus ([[AGEN]] -2.2%) has received a $200M upfront payment from Bristol-Myers Squibb ([[BMY]] -1.0%) as part of the closing of a license agreement for Agenus' bispecific antibody AGEN1777. AGEN1777, in late preclinical development, is designed to tar...
News, Short Squeeze, Breakout and More Instantly...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. Agenus executives will host a co...
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 46.5% to $0.2183 on volume of 404,016,812 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.09 on volume of 317,123,916 shares PROSHARES TRUST (SQQQ) rose 1.5% to $8.23 on volume of 207,449,647 shares Max...
2024-07-18 12:11:22 ET Agenus Inc (NASDAQ: AGEN) faced a dramatic decline in its stock price on Thursday, plummeting more than 50%, following the US Food and Drug Administration (FDA’s) decision to advise against pursuing accelerated approval for its BOT/BAL colorectal cance...